INCIVEK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INCIVEK (INCIVEK).
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
| Metabolism | Hepatic via CYP3A4; also substrate of P-glycoprotein and OATP1B1. |
| Excretion | Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug). |
| Half-life | Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients. |
| Protein binding | Approximately 97-99% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution (Vd/F) is 750 L (approx. 10.7 L/kg for a 70 kg individual) indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is not determined due to lack of intravenous formulation; food increases exposure by 2-3 fold (taken with meals). |
| Onset of Action | Rapid reduction in HCV RNA is observed within 24 hours after oral administration; maximal effect on viral load occurs by day 3. |
| Duration of Action | Duration of action is 24 hours due to thrice-daily dosing; steady-state achieved by day 7. Clinical effect maintained throughout dosing interval. |
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
| Dosage form | TABLET |
| Renal impairment | No dose adjustment is required for mild to moderate renal impairment (CrCl >30 mL/min). Insufficient data for severe renal impairment (CrCl ≤30 mL/min) or hemodialysis; use with caution. |
| Liver impairment | Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). No dose adjustment for mild hepatic impairment (Child-Pugh Class A). |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. No recommended dosing. |
| Geriatric use | No specific dose adjustment recommended; select dose cautiously due to potential age-related decreases in renal function and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INCIVEK (INCIVEK).
| Breastfeeding | It is unknown if telaprevir is excreted in human milk. Due to potential for adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose. M/P ratio is not available. |
| Teratogenic Risk | INCIVEK (telaprevir) is contraindicated in pregnancy due to teratogenic effects observed in animal studies. In the first trimester, there is a risk of major birth defects; in second and third trimesters, fetal harm cannot be ruled out. Pregnancy must be excluded before initiation, and effective contraception must be used during treatment and for 6 months after last dose. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to boceprevir","Coadministration with drugs highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations are associated with serious events (e.g., alfuzosin, amiodarone, pimozide, ergot derivatives, HMG-CoA reductase inhibitors, sildenafil for pulmonary hypertension, triazolam, midazolam, etc.)","Coadministration with rifampin, St. John's wort, carbamazepine, phenobarbital, phenytoin"]
| Precautions | ["Anemia and neutropenia: increased risk with peginterferon alfa and ribavirin","Serious skin reactions including Stevens-Johnson syndrome and erythema multiforme","Cardiac arrhythmias, including bradycardia, in patients with hepatic impairment or taking other drugs","Use with caution in patients with hepatic decompensation"] |
Loading safety data…
| Fetal Monitoring | Pregnancy testing must be performed prior to initiation, during treatment (monthly), and for 6 months after discontinuation. Monitor for rash, anemia (CBC monthly), and hepatic function (AST, ALT, bilirubin every 2 weeks initially, then monthly). Fetal ultrasound if indicated. |
| Fertility Effects | Telaprevir has not been studied for effects on human fertility. In animal studies, no impairment of mating or fertility was observed at systemic exposures lower than clinical exposure. However, ribavirin component in standard regimen is known to cause reversible infertility in males and may impair female fertility. |